Most peptide practices discover ad policy the same way they discover merchant-account risk: after something stops working. An ad account is disabled overnight, a campaign that ran for months is suddenly limited, and the appeal form returns a one-line answer citing a policy the owner has never read.
The frustrating part is that neither platform publishes a rulebook written for this industry. Google has no standalone peptide policy, and Meta expressly reserves the right to decide for itself what counts as an unsafe substance. What's left is a set of general drug and supplement rules, applied by automated systems that read your ad, your landing page, and your wider site together.
This guide explains how each platform is likely to read a peptide clinic's advertising, which claims are consistently the problem, and how to build ads that a regulator, a payment underwriter, and a platform reviewer could all read without wincing.
Why ad policy is a continuity issue, not a marketing issue
Enforcement rarely stays inside the ad platform. The claims that get an ad rejected are the same claims a state board, a bank's underwriter, or an FDA reviewer will read on your website. A clinic whose ads promise outcomes for an unapproved compound has created dated, screenshot-ready evidence of exactly the conduct those reviewers look for.
Payment risk is the downstream version of this problem, and we cover it in why peptide merchant accounts get frozen. Ad policy is the upstream cause. Fixing the claims once fixes both exposures.
How Google reads a peptide ad
Google's unapproved substances policy is the one that matters most here. In summary, it targets products that aren't government approved but are marketed as safe or effective for preventing, curing, or treating a disease; products that imply they're as effective as prescription drugs; products that have been subject to government or regulatory action or warning; and products with names confusingly similar to an unapproved pharmaceutical. Google also points advertisers to LegitScript for the categories it monitors.
Two things trip clinics up in practice:
- Efficacy language. Words that imply a compound heals, repairs, or treats a condition read as a disease claim for an unapproved product, whatever the underlying science says.
- Comparison to approved drugs. Copy that implies equivalence to a branded prescription medication is a named concern in the policy.
Industry agencies also report that specific compound names in headlines are a frequent disapproval trigger. That's unofficial guidance rather than published policy, so treat it as a reason to review your copy carefully, not as a rule.
The July advisory vote does not change any of this. Both platforms look at approval status and claims. An advisory committee recommendation is neither. Our breakdown of what the July 2026 PCAC vote actually changed explains why the regulatory status of these peptides hasn't moved.
How Meta reads a peptide ad
Meta's drugs and pharmaceuticals policy bars ads that promote the sale or use of illicit or recreational drugs, or other unsafe substances, products, or supplements, as determined by Meta at its sole discretion. Ads for prescription drugs must meet a separate set of requirements.
Two consequences follow. First, there's no public list of restricted substances, so the same ad can be approved one month and rejected the next — keep dated records of every approval. Second, the policy does allow ads that refer to restricted substances for news, awareness, or advocacy purposes, provided they don't promote the sale or consumption of those substances. That distinction is the safest lane available to an educational or professional-membership business.
Policy trackers and trade press also report that compounded GLP-1 advertising faces heavy restriction on Meta, that telehealth ads are expected to state the regulatory pathway of any product mentioned, and that state attorneys general have urged Meta to restrict compounded weight-loss ads further. These are secondary reports, so verify against the current policy text before building a campaign around them.
Which claims carry the most risk
This table is our editorial assessment of how automated review and human reviewers tend to read common approaches. It is not a table either platform has issued.
| Approach | How it tends to be read | Risk |
|---|---|---|
| Educational content on regulation, quality, or safety, with no sale of a product | Informational. Meta's policy expressly permits reference for news and awareness. | LOWER |
| Promoting a licensed clinical consultation, without naming compounds | Healthcare service. Still subject to health-claim rules and rules against implying you know a viewer's condition. | MODERATE |
| Naming a specific peptide alongside benefit claims (heals, repairs, anti-aging) | Reads as promoting an unapproved substance as safe or effective. | HIGH |
| Comparing to an approved drug ("same as" or "like" a branded medication) | Implied equivalence to a prescription drug, a named concern in Google's policy. | HIGH |
| Before-and-after images or guaranteed outcomes | Broadly restricted for health and weight-loss advertising. | HIGH |
| Ad lands on a page with dosing, reconstitution, or buy-now buttons for a research-labeled compound | Landing page reveals sale of an unapproved substance, whatever the ad says. | VERY HIGH |
What not to do after a disapproval
A disapproval is a chance to fix the claim. It becomes an account-ending event when advertisers respond by hiding the claim instead. Platforms typically treat evasion as a separate and more serious violation than the original problem.
- Do not show reviewers one page and users another, or swap the landing page after approval.
- Do not disguise restricted terms with misspellings, symbols, or coded language.
- Do not open new accounts to continue after a suspension — this is the ad-platform version of the transaction laundering problem, and it makes recovery harder, not easier.
- Do not resubmit an unchanged ad. Repeated violations escalate.
If your business model depends on language the platforms won't accept, the answer is a different acquisition channel, not a cleverer ad.
Pre-flight checklist for clinics
- Audit every page an ad can reach, not just the ad text — reviewers read the landing page and the wider site.
- Remove disease and efficacy claims for any compound without FDA approval.
- Never compare a compounded or unapproved product to an approved drug.
- Name the licensed prescriber and state licensure. Frame the service as clinical evaluation, not product sale.
- Do not imply guaranteed access to any compounded product. State the regulatory pathway accurately.
- Archive every ad, landing page version, and approval or disapproval notice with dates.
- Build a second acquisition channel (email list, referrals, organic) so one disabled account is an inconvenience, not a shutdown.
- Have counsel who knows your state's rules review campaign copy before launch.
Frequently asked questions
Can a peptide clinic advertise at all on Google and Meta?
It depends on the substance's approval status, how the service is framed, and the platform. Ads for FDA-approved products run through prescription-drug pathways. Ads for unapproved compounds are the ones both platforms are most likely to prohibit. Read the current policy text and confirm with counsel before spending.
Did the July 2026 PCAC vote make advertising easier?
No. The vote was an advisory recommendation and did not change any substance's approval or Bulks List status. Platform reviewers apply approval status and claims, not committee sentiment.
What should I do first after a disapproval?
Save the notice and screenshots, identify the specific claim or page element cited, fix it on the ad and the landing page, and appeal with the corrected version. Do not resubmit unchanged.
Ad policy and access risk move together. APA's Regulations & Compliance Committee tracks the regulatory developments that shape what platforms and payment partners will accept, and members bring questions like these to the Compliance Corner. Our access advocacy program and forms library cover the wider picture.
General information only, not legal advice. Platform policies are enforced at each platform's discretion and change without notice. Sources: Google Ads unapproved substances policy and Meta drugs and pharmaceuticals policy, reviewed September 25, 2026.